Cutaneous squamous cell carcinoma: from biology to therapy
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in
humans, with an estimated incidence of 1 million cases each year in the United States …
humans, with an estimated incidence of 1 million cases each year in the United States …
International liver transplantation society consensus statement on immunosuppression in liver transplant recipients
Effective immunosupression management is central to achieving optimal outcomes in liver
transplant recipients. Current immunosuppression regimens and agents are highly effective …
transplant recipients. Current immunosuppression regimens and agents are highly effective …
[HTML][HTML] European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention
Invasive cutaneous squamous cell carcinoma (cSCC) is one of the most common cancers in
the white populations, accounting for 20% of all cutaneous malignancies. Factors implicated …
the white populations, accounting for 20% of all cutaneous malignancies. Factors implicated …
Sirolimus and secondary skin-cancer prevention in kidney transplantation
S Euvrard, E Morelon, L Rostaing… - … England Journal of …, 2012 - Mass Medical Soc
Background Transplant recipients in whom cutaneous squamous-cell carcinomas develop
are at high risk for multiple subsequent skin cancers. Whether sirolimus is useful in the …
are at high risk for multiple subsequent skin cancers. Whether sirolimus is useful in the …
Practical recommendations for long-term management of modifiable risks in kidney and liver transplant recipients: a guidance report and clinical checklist by the …
Short-term patient and graft outcomes continue to improve after kidney and liver
transplantation, with 1-year survival rates over 80%; however, improving longer-term …
transplantation, with 1-year survival rates over 80%; however, improving longer-term …
Cancer in kidney transplant recipients
Cancer is the second most common cause of mortality and morbidity in kidney transplant
recipients after cardiovascular disease. Kidney transplant recipients have at least a twofold …
recipients after cardiovascular disease. Kidney transplant recipients have at least a twofold …
Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data
GA Knoll, MB Kokolo, R Mallick, A Beck… - Bmj, 2014 - bmj.com
Objective To examine risk of malignancy and death in patients with kidney transplant who
receive the immunosuppressive drug sirolimus. Design Systematic review and meta …
receive the immunosuppressive drug sirolimus. Design Systematic review and meta …
[HTML][HTML] Skin cancers in organ transplant recipients
A Mittal, OR Colegio - American Journal of Transplantation, 2017 - Elsevier
Long-term utilization of immunosuppression in organ transplant recipients (OTRs) leads to
decreased immune-mediated tumor surveillance and development of malignant tumors. A …
decreased immune-mediated tumor surveillance and development of malignant tumors. A …
Cancer in the transplant recipient
Malignancy has become one of the three major causes of death after transplantation in the
past decade and is thus increasingly important in all organ transplant programs. Death from …
past decade and is thus increasingly important in all organ transplant programs. Death from …
[HTML][HTML] ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious …
Background The present review is part of the European Society of Clinical Microbiology and
Infectious Diseases (ESCMID) Study Group for Infections in Compromised Hosts (ESGICH) …
Infectious Diseases (ESCMID) Study Group for Infections in Compromised Hosts (ESGICH) …